Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $2.7 million.

  • Sutro Biopharma's Change in Account Payables rose 228130.08% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 6791.28%. This contributed to the annual value of $706000.0 for FY2024, which is 8532.83% down from last year.
  • Per Sutro Biopharma's latest filing, its Change in Account Payables stood at $2.7 million for Q3 2025, which was up 228130.08% from -$3.8 million recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's Change in Account Payables peaked at $4.1 million during Q4 2024, and registered a low of -$3.8 million during Q2 2025.
  • Over the past 5 years, Sutro Biopharma's median Change in Account Payables value was -$462000.0 (recorded in 2021), while the average stood at $208315.8.
  • As far as peak fluctuations go, Sutro Biopharma's Change in Account Payables crashed by 105808.08% in 2024, and later skyrocketed by 228130.08% in 2025.
  • Over the past 5 years, Sutro Biopharma's Change in Account Payables (Quarter) stood at -$1.8 million in 2021, then skyrocketed by 47.24% to -$937000.0 in 2022, then soared by 532.98% to $4.1 million in 2023, then increased by 1.58% to $4.1 million in 2024, then crashed by 34.89% to $2.7 million in 2025.
  • Its Change in Account Payables was $2.7 million in Q3 2025, compared to -$3.8 million in Q2 2025 and -$1.9 million in Q1 2025.